| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:00 - 08:20 | Registration | ||||||
| 08:20 - 08:30 | Opening Remark |
Shou-Tung Chen
|
|||||
| 08:30 - 08:40 | [Young Investigator Presentation] Investigating the Connection Between LSM1 and Energy Metabolism in Breast Cancer through Spatial Transcriptome and Single-Cell RNA Sequencing |
Yen-Dun Tony Tzeng
|
Chen-Hsiang Chang
|
||||
| 08:40 - 08:50 | [Young Investigator Presentation] Unveiling the Molecular Mechanism of Endocrine Resistance: Insights from Epigenetic Reprogramming and Coupled Transcription Factors in Estrogen Receptor Positive Breast Cancer |
An-Chieh Feng
|
Chen-Hsiang Chang
|
||||
| 08:50 - 09:00 | [Young Investigator Presentation] Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study |
Han-Fang Cheng
|
Chen-Hsiang Chang
|
||||
| 09:00 - 09:30 | Immune Checkpoint Inhibitor in Neoadjuvant or Adjuvant Setting for Breast Cancer: the Paradigm Shift |
Sibylle Loibl
|
Yuan-Ching Chang
|
Video | |||
| 09:30 - 10:00 | Management of ER+ HER2- mBC: Bringing Together Clinical & Real-World Evidence |
Adam M. Brufsky
|
Dar-Ren Chen
|
Video | |||
| 10:00 - 10:30 | Coffee Break | ||||||
| 10:30 - 11:00 | Management of Older Patients with Breast Cancer |
Etienne Brain
|
King-Jen Chang
|
Video | |||
| 11:00 - 11:15 | Management of Ipsilateral Local Recurrence: Surgical View |
Han-Byoel Lee
|
Chao-Ming Hung
|
Video | |||
| 11:15 - 11:30 | Management of Ipsilateral Local Recurrence: Radiation Oncology View |
Chin-Nan Chu
|
Huan-Ming Hsu
|
Video | |||
| 11:30 - 11:55 | Supraclavicular axillary disease management |
Shih-Che Shen
|
Wen-Hung Kuo
|
Video | |||
| 11:55 - 12:10 | Contralateral axillary disease management |
Soong June Bae
|
Frank Fu Ou-Yang
|
Video | |||
| 12:10 - 12:30 | Panel Discussion |
Byung Joo Chae
Jun Won Min
Kuo-Ting Lee
Chiao Lo
|
Chin-Yao Lin
|
||||
| 12:30 - 13:10 | [Luncheon Symposium] Interpret the Role of GnRH Agonist from Clinical Trial into Local Practice in Early Breast Cancer |
Ming-Yang Wang
|
Yao-Jen Chang
|
Video | |||
| 13:00 - 13:30 | Break | ||||||
| 13:30 - 14:00 | Reducing the Risk of Recurrence in HR+, HER2- High-Risk Early Breast Cancer |
Hiroko Masuda
|
Ling-Ming Tseng
|
Video | |||
| 14:00 - 14:30 | Gene Assay tools to Inform Chemotherapy Benefit in HR+ HER2- Anatomically High Risk Early Breast Cancer |
Kevin Kalinsky
|
Cheng-Ping Yu
|
Video | |||
| 14:30 - 15:00 | Exploring the Potential of Ribociclib and Endocrine Therapy in Early Breast Cancer: Findings from the NATALEE Trial |
Stephen Chia
|
Chiun-Sheng Huang
|
Video | |||
| 15:00 - 15:30 | Panel Discussion: Adjuvant treatment for HR+ HER2-EBC, more or less |
Hiroko Masuda
Kevin Kalinsky
Stephen Chia
Chin-Sheng Hung
Jiun-I Lai
|
Chun-Yu Liu
|
||||
| 15:30 - 15:50 | Coffee Break | ||||||
| 15:50 - 16:20 | Current Treatment Strategies for High-Risk Patients with HER2+ Early-Stage Breast Cancer: Can We Improve Clinical Outcomes |
Miguel Martin
|
Shin-Cheh Chen
|
Video | |||
| 16:20 - 16:50 | Current Challenges in Treating Patients with HER2 positive Breast Cancer: Leave no Options Behind |
Nadia Harbeck
|
Fang-Ming Chen
|
Video | |||
| 16:50 - 17:20 | Shape the Treatment Paradigm of HER2-low MBC: From Guideline to Clinical Practice |
Giuseppe Curigliano
|
Tsu-Yi Chao
|
||||
| 17:20 - 17:50 | Promising New Drugs Development for MBC |
Peter Schmid
|
Ming-Feng Hou
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:00 - 08:10 | Registration | ||||||
| 08:10 - 08:20 | [Oral Presentation]GRK6 recruits the β-Arrestin 2/MAPK/NF-κB signaling axis for promoting the metastatic progression of triple-negative breast cancer |
Wen-Ke Wang
|
Chi-Cheng Huang
|
||||
| 08:20 - 08:40 | [Oral Presentation]A competing risk analysis study of prognosis in patients with HER2-low and HER2-zero breast cancer |
Joseph Lin
|
Chi-Cheng Huang
|
||||
| 08:40 - 08:50 | [Oral Presentation]Exploration of Cuproptosis-Related Hub Genes and Microenvironmental Landscape in Breast Cancer using Integrated Spatial Transcriptome and Single-Cell RNA-Sequencing |
Jui-Hu Hsiao
|
Chi-Cheng Huang
|
||||
| 08:50 - 09:20 | What Can We Expect More from Ribociclib in Treating HR+HER2-mBC Patients? |
Dwan-Ying Chang
|
Fiona Tsui-Fen Cheng
|
Video | |||
| 09:20 - 09:50 | Identification and Characterization of a Proliferative Cell Population in Estrogen Receptor-Positive Metastatic Breast Cancer through Spatial and Single-Cell Transcriptomics |
Shiuan Chen
|
Yen-Shen Lu
|
||||
| 09:50 - 10:35 | Novel Approaches in Triple Negative and HR+/HER2- Metastatic Breast Cancer - Anti-Trop2 ADC and Future Development |
Amy K. Krie
|
Hsien-Kun Chang
|
||||
| 10:35 - 10:50 | Award Ceremony ＆Coffee Break | ||||||
| 10:50 - 11:20 | Progress of Biomarker Development for Breast Cancer |
Aleix Prat
|
Jyh-Cherng Yu
|
||||
| 11:20 - 11:50 | Local Regional Management for Patients after Neoadjuvant Therapy |
Mehra Golshan
|
Shyr-Ming Sheen-Chen
|
Video | |||
| 11:50 - 12:25 | Managing ER-Positive, HER2-Negative Advanced Breast Cancer, A Long Journey |
Junichiro Watanabe
|
Kun-Ming Rau
|
Video | |||
| 12:25 - 12:45 | Early Breast Cancer Therapy Advancements: Pegylated Liposomal Doxorubicin as a Viable Option |
Chung-Liang Li
|
Guo-Shiou Liao
|
Video | |||
| 12:45 - 13:10 | [Luncheon Symposium] Refining the Role of Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia |
Ming-Shen Dai
|
Ta-Chung Chao
|
Video | |||
| 13:10 - 13:40 | Does the Sequence of Anthracycline and Taxane Matter in Chemotherapy of Early Breast Cancer? |
Hsu-Huan Chou
|
Liang-Chih Liu
|
Video | |||
| 13:40 - 14:10 | Filling the Gap after CDK4/6 Inhibitor: The Evolving Treatment Landscape of Patients with HR+/HER2- mBC |
Ching-Hung Lin
|
Hsien-Tang Yeh
|
Video | |||
| 14:10 - 14:40 | Break | ||||||
| 14:40 - 15:10 | Bone Health and Orthopedic Risk Management in Breast Cancer Patients |
Po-Hsiang Huang
|
Yao-Lung Kuo
|
Video | |||
| 15:10 - 15:40 | Current Experience and Future Perspective in Conducting Biosimilar Clinical Trials in Taiwan |
Chiun-Sheng Huang
|
Shou-Tung Chen
|
Video | |||
| 15:40 - 16:10 | How to Sequence Treatment therapies in HR+ and LN+EBC |
Yi-Fang Tsai
|
Shen-Liang Shih
|
||||
| 16:10 - 16:40 | Do We need MRI Study Before and After Neoadjuvant Chemotherapy? |
Si-Wa Chan
|
Chih-Chiang Hung
|
Video | |||
| 16:40 - 17:00 | Closing |
Shou-Tung Chen
|